Announcements
- Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
- Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
- Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
- Life Science Cares Launches in Switzerland
- Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2024
- Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
- Molecular Partners Announces Dismissal of Class Action Lawsuit
- Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
- Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
More ▼
Key statistics
On Friday, Molecular Partners AG (6ML0:STU) closed at 3.28, 38.98% above the 52 week low of 2.36 set on Jun 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.30 |
---|---|
High | 3.52 |
Low | 3.28 |
Bid | 3.02 |
Offer | 3.86 |
Previous close | 3.32 |
Average volume | 0.00 |
---|---|
Shares outstanding | 36.68m |
Free float | 33.17m |
P/E (TTM) | -- |
Market cap | 138.09m USD |
EPS (TTM) | -1.97 USD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼